Circulating Tumor DNA as Liquid Biopsy in Patients With Stage IV Solid Tumors, a Feasibility Study at MUSC HCC
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Detecting specific cancer mutations in ctDNA isolated from plasma of stage IV cancer patients at HCC.
研究概览
简要总结
- To demonstrate the ability to detect specific cancer mutations in ctDNA isolated from plasma of stage IV cancer patients at HCC.
- To compare, in each patient, ctDNA longitudinal samples through treatment, and when available, with those of primary tumor and metastasis.
详细描述
The overall goal of this study is to study circulating tumor DNA (ctDNA) in the blood to determine how cancer cells in patients react to treatment. DNA is short for deoxyribonucleic acid. DNA contains information that determines in part the traits, such as eye color, height, or disease risk, that are passed on from parent to child. This reaction will be measured by studying patient blood that will be collected before and during treatment until there is disease progression.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Confirmed diagnosis of stage IV malignancy, including any advanced solid tumors (including lymphoma)
- •Eastern Cooperative Oncology Group (ECOG) performance Status (PS) 0-3
- •Life expectancy ≥ 3 months
- •Patients must be able to provide consent
- •Patients can be enrolled in other interventional clinical trials
排除标准
- •Age < 18-year-old
结局指标
主要结局
Detecting specific cancer mutations in ctDNA isolated from plasma of stage IV cancer patients at HCC.
时间窗: 24 months
Changes in patients' ctDNA longitudinal samples through treatment, and when available, of primary tumor and metastasis.
时间窗: 24 months
次要结局
未报告次要终点
